Patient Gateway

RSS Feed

Astellas begins Phase III trial of setidegrasib in KRAS G12D mutated advanced lung cancer

Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC

What EGFR and KRAS G12C Results Tell Clinicians Beyond Treatment Selection

Astellas begins patient dosing in phase 3 study of setidegrasib in previously treated KRAS G12D- mutated advanced non-small cell lung cancer

Closing the Gap in First-Line Treatment of KRAS G12C–Mutated Advanced NSCLC: From Biology to Bedside Decisions and Trial-Ready Care

September 2026 NCCN NSCLC Updates Expand Precision Therapy: Sevabertinib Moves Into First Line and Daraxonrasib Enters the KRAS-Mutant Landscape

What EGFR and KRAS G12C Results Tell Clinicians Beyond Treatment Selection